Vanguard Capital Management
BDTX icon

Vanguard Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Vanguard Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93M Buy
2,125,270
+274,802
+15% +$672K ﹤0.01% 3206
2026
Q1 		$3.94M Buy
+1,850,468
New +$4.4M ﹤0.01% 3146

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management's BDTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 15% in Q2 2026, buying an estimated $672K and bringing the position to 2,125,270 shares worth $3.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3206.

Vanguard Capital Management first reported a position in BDTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.94M in Q1 2026. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Vanguard Capital Management held 2,125,270 shares of Black Diamond Therapeutics worth $3.93M as of Q2 2026.
  • Vanguard Capital Management bought 274,802 Black Diamond Therapeutics shares in Q2 2026, an estimated $672K.
  • Black Diamond Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3206 holding.
  • Vanguard Capital Management first reported a position in Black Diamond Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Black Diamond Therapeutics position peaked at $3.94M in Q1 2026.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.